What is Zacks Research's Estimate for Integer Q3 Earnings?

Key Points

• Zacks Research lowered Integer’s Q3 2026 EPS estimate to $1.63 from $1.68, while maintaining a Hold rating. Its current full-year consensus estimate is $6.08 per share.
• Integer’s latest quarterly results exceeded expectations, with EPS of $1.60 versus the $1.38 consensus and revenue of $464.11 million versus $451.07 million expected. However, revenue declined 2.6% year over year.
• Wall Street sentiment remains cautious: the stock has a consensus Hold rating from analysts and a consensus price target of $109.86, below its reported $124.90 opening price.

Integer Holdings Corporation (NYSE:ITGR - Free Report) - Analysts at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for Integer in a research report issued on Monday, August 24th. Zacks Research analyst Team now forecasts that the medical equipment provider will earn $1.63 per share for the quarter, down from their previous estimate of $1.68. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Integer's current full-year earnings is $6.08 per share. Zacks Research also issued estimates for Integer's Q4 2026 earnings at $1.70 EPS, FY2026 earnings at $6.13 EPS, Q1 2027 earnings at $1.46 EPS, Q2 2027 earnings at $1.61 EPS, Q3 2027 earnings at $1.72 EPS, Q4 2027 earnings at $1.77 EPS, FY2027 earnings at $6.56 EPS, Q1 2028 earnings at $1.71 EPS, Q2 2028 earnings at $1.63 EPS and FY2028 earnings at $6.85 EPS.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The medical equipment provider reported $1.60 EPS for the quarter, beating the consensus estimate of $1.38 by $0.22. Integer had a return on equity of 12.79% and a net margin of 6.97%.The company had revenue of $464.11 million during the quarter, compared to analysts' expectations of $451.07 million. During the same quarter in the previous year, the business earned $1.55 EPS. The firm's revenue was down 2.6% on a year-over-year basis.

Several other brokerages have also recently issued reports on ITGR. Citigroup boosted their price objective on shares of Integer from $92.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, July 8th. Wells Fargo & Company increased their target price on Integer from $84.00 to $127.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 4th. Raymond James Financial cut Integer from a "moderate buy" rating to a "hold" rating in a report on Monday, August 3rd. Oppenheimer downgraded Integer from an "outperform" rating to a "market perform" rating in a research report on Monday, August 3rd. Finally, Truist Financial lowered Integer from a "buy" rating to a "hold" rating and upped their price target for the stock from $110.00 to $127.00 in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $109.86.

Integer Stock Performance

NYSE:ITGR opened at $124.90 on Tuesday. The company has a quick ratio of 2.41, a current ratio of 3.73 and a debt-to-equity ratio of 0.75. The company has a market cap of $4.25 billion, a P/E ratio of 34.12, a P/E/G ratio of 2.96 and a beta of 0.61. Integer has a fifty-two week low of $62.00 and a fifty-two week high of $126.14. The firm's 50 day moving average is $104.80 and its two-hundred day moving average is $93.42.

Institutional Investors Weigh In On Integer

Several large investors have recently made changes to their positions in ITGR. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Integer during the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC increased its holdings in Integer by 48.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 117 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in Integer by 1,037.5% in the 4th quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 415 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Integer by 135.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 267 shares during the period. Finally, Arax Advisory Partners raised its position in Integer by 2,489.5% in the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 473 shares during the period. Institutional investors and hedge funds own 99.29% of the company's stock.

Key Integer News

Here are the key news stories impacting Integer this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to $6.13 from $6.05, while also increasing its Q2 2027 estimate to $1.61 from $1.60 and Q1 2028 estimate to $1.71 from $1.65. These revisions indicate some confidence in Integer’s medium-term earnings trajectory.
• Neutral Sentiment: Zacks maintained a Hold rating on Integer. Its current full-year consensus estimate remains $6.08 per share, while its FY2027 and FY2028 forecasts stand at $6.56 and $6.85, respectively.
• Neutral Sentiment: A law firm announced an opportunity for Integer investors to participate in a reported fraud investigation. The notice does not provide substantive details about the allegations or indicate any confirmed wrongdoing, but such announcements can add uncertainty for shareholders. ITGR Investors Have Opportunity to Join Integer Holdings Corporation Fraud Investigation with SBS Law
• Negative Sentiment: The broader Zacks update was unfavorable: estimates were reduced for Q3 2026 EPS to $1.63 from $1.68, Q4 2026 to $1.70 from $1.77, Q1 2027 to $1.46 from $1.50, Q3 2027 to $1.72 from $1.87, Q4 2027 to $1.77 from $1.90, FY2027 to $6.56 from $6.87, Q2 2028 to $1.63 from $1.74, and FY2028 to $6.85 from $7.20. The cuts suggest analysts see weaker near- to long-term earnings potential than previously expected.

About Integer

Integer Holdings Corporation NYSE: ITGR is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer's product portfolio is organized into two core segments: Advanced Delivery and MedTech.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source